Research programme: antibody drug conjugates - Aspyrian TherapeuticsAlternative Names: Near-infrared Photoimmunotherapy; PIT - Aspyrian Therapeutics
Latest Information Update: 31 Mar 2014
At a glance
- Originator Aspyrian Therapeutics
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Cell membrane modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 01 Mar 2014 Preclinical trials in Cancer in USA (Parenteral)